Flipping Book - Brain Tumours

A phase 1 study evaluating ABT-414 in combination with

temozolomide (TMZ) for subjects with recurrent or unresectable

glioblastoma (GBM).

2014 ASCO Annual Meeting

• Antibody targeting EGFR or mutant EGFRvIII conjugated to a cytotoxic anti-

microtubule agent

• Preclinical activity against GBM tumor models - either amplified wild type

EGFR or EGFRvIII

• Preliminary safety data demonstrate unique toxicity - corneal epithelial

microcysts

• Preliminary responses in 3/9 pts with TMZ refractory GBM; 1 CR

• Phase 2 studies of ABT-414 in GBM underway:

–

With TMZ in recurrent GBM (EGFR amplified or EGFRvIII mutated)

–

With RT-TMZ in first line GBM (EGFR amplified or EGFRvIII mutated)